Cargando…
Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach
DDX3 is an RNA helicase with oncogenic properties. The small molecule inhibitor RK-33 is designed to fit into the ATP binding cleft of DDX3 and hereby block its activity. RK-33 has shown potent activity in preclinical cancer models. However, the mechanism behind the antineoplastic activity of RK-33...
Autores principales: | Heerma van Voss, Marise R., Kammers, Kai, Vesuna, Farhad, Brilliant, Justin, Bergman, Yehudit, Tantravedi, Saritha, Wu, Xinyan, Cole, Robert N., Holland, Andrew, van Diest, Paul J., Raman, Venu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050443/ https://www.ncbi.nlm.nih.gov/pubmed/29684792 http://dx.doi.org/10.1016/j.tranon.2018.04.001 |
Ejemplares similares
-
Role of DDX3 in the pathogenesis of inflammatory bowel disease
por: Tantravedi, Saritha, et al.
Publicado: (2017) -
Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment
por: Heerma van Voss, Marise R., et al.
Publicado: (2017) -
Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer
por: van Voss, Marise R. Heerma, et al.
Publicado: (2015) -
Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33
por: Tantravedi, Saritha, et al.
Publicado: (2018) -
Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer
por: Heerma van Voss, Marise R, et al.
Publicado: (2017)